TRACK-TBI NET is a multi-faceted Phase 2 TBI clinical trial network that builds on the well-established infrastructure of its foundation: the longitudinal, observational TRACK-TBI study. This institutional and public-private partnership is comprised of 18 Clinical Enrollment/Study Sites, 7 Cores, and a Contract Research Organization, for a total of nearly 50 collaborating institutions, corporations, and philanthropic organizations. Following a decade of progress, the TRACK-TBI NETWORK is strategically positioned to transition from an observational natural history study to a robust platform for TBI intervention trials. Funded in part by the United States Department of Defense US Army Medical Materiel Development Activity (DoD USAMMDA) via the Medical Technology Enterprise Consortium, TRACK-TBI NET invites all members of the TBI research community, across academic, public, and private platforms, to propose candidate pharmaceutical agents for Phase 2 studies.